Published in final edited form as:

J Nat Prod. 2006 April ; 69(4): 536–541.

Serotonergic Activity-Guided Phytochemical Investigation of the Roots of *Angelica sinensis*

Shixin Deng, Shao-Nong Chen, Ping Yao, Dejan Nikolic, Richard B. van Breemen, Judy L. Bolton, Harry H.S. Fong, Norman R. Farnsworth, and Guido F. Pauli*

UIC/NIH Center for Botanical Dietary Supplements Research and Program for Collaborative Research in the Pharmaceutical Sciences, Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, University of Illinois at Chicago, Chicago, IL, 60612

Abstract

Serotonin receptor (5-HT₇) binding assay-directed fractionation of a methanol extract of the dried roots of *Angelica sinensis* (Apiaceae) led to the isolation and identification of twenty-one compounds including a new phenolic ester, angeliferulate (**1**), and three new phthalides, 10-angeloylbutylphthalide (**2**), sinaspirolide (**3**) and ansaspirolide (**4**), along with seventeen known compounds, *p*-hydroxyphenethyl *trans*-ferulate (**5**), *Z*-ligustilide (**6**), *Z*-butylidenephthalide (**7**), senkyunolide I (**8**), *Z*-6-hydroxy-7-methoxy-dihydroligustilide (**9**), *N*-butylbenzenesulphonamide (**10**), 11(*S*),16(*R*)-dihydroxy-octadeca-9*Z*,17-dien-12,14-diyn-1-yl acetate (**11**), (3*R*,8*S*)-faltarindiol (**12**), heptadeca-1-ene-9,10-epoxy-4,6-diyn-3,8-diol (**13**), oplopandiol (**14**), 8-hydroxy-1-methoxy-, *Z*-9-heptadecene-4,6-diyn-3-one (**15**), imperatorin, ferulic acid, vanillin, stigmasterol, sucrose, and 1,3-di-linolenin. This is the first report of a sulfonamide (**10**) identified from a higher plant source, although its presence needs further investigation. Biosynthetic pathways for dimeric phthalides **3** and **4** are proposed. Compound **5**, **7**, **11**, **12**, **15**, and imperatorin exhibited affinity toward 5-HT₇ receptors in a competitive binding assay.

Angelica sinensis (Oliv.) Diels (Apiaceae) is an herbaceous perennial plant mainly distributed in the northwest of China. The root is variously called Dang Gui or Dong Quai, among others. It has been traditionally applied to the treatment of gynecological disorders (e.g. menstrual disorders, amenorrhea, dysmenorrhea, anemia, premenstrual syndrome, menopause) for thousands of years in Asia, with the earliest record of its use in the *Divine Husbandman's Classic of the Materia Medica* (Shen Nong Ben Cao Jing) published during the period of the Han Dynasty (AD 25–225).^{1–3} Dang Gui has been regarded as “lady’s ginseng” or “female’s ginseng”, implicating its popularity and importance for various women’s ailments. It was first introduced into the West in 1899 by Merck in the form of a liquid extract named “Eumenol”,⁴ and is presently marketed in the USA as a dietary supplement, with numerous products being marketed worldwide.

It was generally presumed that Dang Gui has estrogenic activity based on its broad applications for female ailments. However, there is no evidence of estrogenicity in both *in vitro* and clinical studies,^{5,6} which indicates that Dang Gui may act through an alternative mechanism rather than being a phytoestrogen. Indeed, preliminary testing of extracts demonstrated that the methanol extract of Dang Gui has serotonergic activity, suggesting that it may contain serotonergic ligands that act on serotonin receptors and, thus, exhibit pharmacological effects related to improvement of symptoms of moods, behaviors and hot flashes for premenstrual and menopausal women.

* To whom correspondence should be addressed. Tel (312) 355-1949. Fax (312)-355-2693. E-mail: gfp@uic.edu..

Previous phytochemical studies on Dang Gui have resulted in the isolation and identification of a variety of constituent classes, including phthalides, polysaccharides, lipids, polyacetylenes, aromatic compounds, terpenes, amino acids, trace elements, and vitamins.^{7–13} The root contains up to 0.65% volatile oil with alkylphthalides being the major components, of which, *Z*-ligustilide is the most abundant with up 45%–60%.^{9,11,14–16}

Other alkylphthalides identified so far include the phthalide monomers *E*-ligustilide, butyridenephthalide, butylphthalide, senkyunolide A-I, senkyunolide K, *Z*-6-hydroxy-7-methoxy-dihydroligustilide, *Z*-6,7-epoxyligustilide, sedanenolide, neocnidilide, 3-butyridene-7-hydroxyphthalide, 11-angeloylsenkyunolide F, and *E*-6,7-dihydroxydihydroligustilide.^{11,14–18} In addition to these phthalide monomers, several dimeric phthalides, angelicide,^{9,11} *E*-232,¹⁹ *Z,Z'*-3,3',8,8'-diligustilide, *Z,Z'*-6,8',7,3'-diligustilide, levistolide A¹¹ and *Z*-3',8',3'a,7'a-tetrahydro-6,3',7,7'a-diligustilide-8'-one²⁰ have also been reported. These dimers were thought to be derived through cycloaddition reactions, with or without further oxidation or ring cleavage of various phthalide monomers.^{19,21,22}

The long-term aim of our research is to investigate a potential mechanism underlying Dang Gui's use in a wide range of gynecological indications, particularly those associated with PMS and menopause, and to chemically and biologically characterize the crude extract in order to provide a standardized clinical formulation. Toward this end, the bioactive phytochemicals of Dang Gui were investigated guided by the 5-HT₇ receptor-binding assay. The present paper describes the isolation and identification of twenty-one compounds including a new phenolic ester, angeliferulate (**1**), and three new phthalides, 10-angeloylbutylphthalide (**2**), sinaspirolide (**3**) and ansaspirolide (**4**), along with seventeen known compounds, as well as the serotonergic (5-HT₇) effect of these isolates.

Results and Discussion

In our initial biological study, a methanol extract of the dried roots of Dang Gui exhibited serotonergic activity with a 59.0 ± 4.0 % inhibition on [³H] LSD binding to the 5-HT₇ receptor. The serotonergic active methanol extract was successively partitioned with petroleum ether (PE), chloroform (CHCl₃), and *n*-butanol (*n*-BuOH), and the partitions, along with aqueous mother liquor, were evaluated for their serotonergic activity in the same bioassay. The bioactivity was localized in the PE and CHCl₃ partitions. Bioassay-guided chromatographic fractionation of the PE and CHCl₃ extracts afforded twenty-one compounds. Four of these were new compounds (**1–4**), one phenolic ester and three phthalides. The new phenolic ester was named angeliferulate (**1**), and the three new phthalides given the trivial names of 10-angeloylbutylphthalide (**2**), sinaspirolide (**3**), and ansaspirolide (**4**) to reflect the nature of their cyclic arrangements, respectively. The remaining 17 compounds were identified as known compounds by comparison of their spectroscopic data with those reported previously in the literature or with those of previously authenticated reference samples.

Compound **1** was obtained as pale yellow oil. The IR spectrum of **1** exhibited characteristic absorption bands at 3385, 1701, 1600 and 1515 cm⁻¹, suggesting the presence of a hydroxyl, an α , β -unsaturated ester carbonyl, and an aromatic moieties, respectively. The HRESIMS spectrum showed a deprotonated molecule of *m/z* 403.1380 (calcd for 403.1393), corresponding to a molecular formula of C₂₁H₂₄O₈ containing ten degrees of unsaturation. The ¹H and ¹³C NMR spectral data of **1** were found to be similar to those of *p*-hydroxyphenethyl *trans*-ferulate **5**, which in turn was identified by comparison of its NMR data with literature data.^{8,23,24} A fragment ion of *m/z* 193 in the CID product ion spectrum suggested the presence of a feruloyl unit.^{25,26} The ¹H NMR spectrum of **1** displayed signals at δ 7.588 (1H, d, *J* = 16.0 Hz) and 6.322 (1H, d, *J* = 16.0 Hz), indicating the presence of two *trans*-coupled olefinic protons, and signals at δ 3.929 (3H, s), 3.889 (3H, s) and 3.278 (3H, s) attributable to three

methoxyl groups. In addition, two sets of 1,3,4-trisubstituted phenyl units (ABX system) were revealed by signals at δ 7.061 (1H, dd, J = 8.2, 2.0 Hz), 7.030 (1H, d, J = 2.0 Hz), 6.915 (1H, d, J = 8.2 Hz), 6.905 (1H, d, J = 8.6 Hz), 6.810 (1H, d, J = 2.0 Hz), 6.806 (1H, dd, J = 8.6, 2.0 Hz), and confirmed by the COSY spectrum. The observed downfield chemical shift of the methylene and methine protons (δ 4.148 (dd, J = 13.0, 3.1 Hz, H-9'a), 3.981 (m, H-9'b), 3.983 (m, H-8') and 4.116 (d, J = 11.8 Hz, H-7') indicated their attachment to the oxygen-bearing carbons (C-9', C-8' and C-7', respectively). The presence of an ester carbonyl group was revealed by a ^{13}C NMR signal at δ 167.4 (C-9). The linkage among the different moieties and the substitution patterns were fully assigned by the HMBC spectrum with the correlations (H-7 $\rightarrow$ C-2; C-6 and C-9; H-8 $\rightarrow$ C-1; H-7' $\rightarrow$ C-2' and C-6'; H-9' $\rightarrow$ C-9 and C-7'). Based on the aforementioned data, compound **1** was identified as a previously unreported phenolic ester, 3-methoxyl-3-(4-hydroxy-3-methoxyphenyl)-2-hydroxy-propyl-3-(4-hydroxy-3-methoxyphenyl)-2*E*-propenoate, and the trivial name of angeliferulate suggested.

Compound **2** was obtained as pale yellow oil. The presence of an α , β -unsaturated lactone ring was suggested by its IR spectrum (λ_{max} at 1765 and 1699 cm^{-1}).²⁷ Its molecular formula was determined as $\text{C}_{17}\text{H}_{20}\text{O}_4$ by HRESIMS. The ESIMSMS experiment resulted in the most abundant fragment ion at m/z 189, which is consistent with that of butylphthalide.¹¹ The ^1H and ^{13}C NMR data of **2** were observed to be similar to those of *Z*-butylidenephthalide (**7**), a compound identified by direct comparison of its spectral data with those reported in the literature.²⁸ Thus, **2** was determined to be a phthalide. The ^1H NMR spectrum of **2** exhibited signals of four aromatic protons at δ 7.912 (1H, dd, J = 7.6, 1.2 Hz), 7.685 (1H, ddd, J = 7.7, 7.6, 1.2 Hz), 7.542 (1H, ddd, J = 7.7, 7.6, 0.8 Hz), 7.427 (1H, dd, J = 7.6, 0.8 Hz, H-4), suggesting the presence of a 1, 2-disubstituted aromatic ring. Two oxygen-bearing methine signals at δ 5.490 (1H, dd, J = 7.2, 3.9 Hz) and 5.000 (1H, m) were coupled with four methylene protons at δ 2.205/1.776 and 1.823/1.721, as well as a methyl group at δ 1.265 (3H, d, J = 6.4 Hz), respectively, as supported by the analysis of the COSY spectrum and their coupling constants. One vinyl proton at δ 6.055 (1H, qq, J = 7.3, 1.5) was observed to be coupled with two vinylic methyls at δ 1.975 (3H, dq, J = 7.3, 1.5) and 1.885 (3H, dq, J = 1.5, 1.5). The ^{13}C NMR spectrum displayed 17 carbons, including two ester carbonyl carbons (δ 170.9, 168.0) and two vinyl carbons (δ 137.9, 128.4). The presence of an angelic acid unit was indicated by a spin system composed of proton signals at δ 6.055 (1H, qq, J = 7.3, 1.5), 1.975 (1H, dq, J = 7.3, 1.5) and 1.885 (1H, dq, J = 1.5, 1.5),²⁹ which was confirmed by an ESIMSMS fragment ion at m/z 83. The connectivity between the butylphthalide and the angelic acid moieties was established by the HMBC correlations between the protons at δ 5.000 (2H, m, H-10) and the quaternary carbon signal at δ 168.0 (C-1'). Thus, compound **2** was elucidated as an angeloyl ester of butylphthalide, and named as 10-angeloylbutylphthalide.

The HRESIMS spectrum of **3** exhibited a protonated molecule of m/z 379.1922 (calcd for 379.1909), suggesting the molecular formula of $\text{C}_{24}\text{H}_{26}\text{O}_4$, with twelve degrees of unsaturation. The strong bands at 1776 and 1700 cm^{-1} in IR spectrum indicated the existence of an α , β -unsaturated lactone ring.¹⁹ The ^1H NMR and COSY spectrum suggested the presence of a butyl side chain [δ 3.016 (1H, dd, J = 7.8, 7.8 Hz, H-8), 1.790 (1H, dddd, J = 14.1, 10.2, 7.8, 5.4, H-9a), 1.510 (1H, dddd, J = 18.0, 10.2, 7.8, 5.4, H-9b), 1.220 (1H, m, H-10a), 1.010 (1H, m, H-10b), 0.776 (3H, t, J = 7.4, H-11)] and a butylidene side chain [δ 4.406 (1H, t, H-8'), 2.246 (1H, m, H-9'a), 2.147 (1H, m, H-9'b), 1.399 (1H, m, H-10'a), 1.256 (1H, m, H-10'b), 0.885 (3H, t, J = 7.4, H-11')]. Two olefinic signals attributable to an isolated double bond [δ 6.113 (1H, ddd, J = 9.8, 6.4, 2.0, H-6') and 5.994 (1H, dd, J = 9.8, 2.8 Hz, H-7')] and four aromatic protons [δ 7.901 (1H, dd, J = 7.4, 1.2 Hz, H-7), 7.710 (1H, td, J = 7.6, 1.2 Hz, H-5), 7.586 (1H, dd, J = 7.6, 7.4 Hz, H-6), 7.577 (1H, brd, J = 7.6 Hz, H-4)] were also observed. The ^{13}C NMR spectrum of **3** exhibited the presence of 24 carbons with two ester carbonyl units [δ 173.9 (C-1'), 168.5 (C-1)], and displayed a resonance pattern very similar to a combination of those of the phthalide monomers *Z*-ligustilide (**6**) and *Z*-butylidenephthalide

(7), except for the substitution of the vinyl carbons of the two double bonds in **6** and **7** with a tertiary and three quaternary carbons in **3** (^{13}C δ 88.5, 53.0, 54.2 and 48.6). These data suggested **3** to be a phthalide dimer composed of one ligustilide and one butylphthalide unit. This conclusion was confirmed by the presence of two prominent fragment ions of m/z 191 and 189 in the product ion spectrum. The ^1H NMR of **3** displayed an olefinic proton of a butylidene side chain at δ 4.406 (1H, t, H-8'), and the upfield shift of this signal indicated that it was not affected by the deshielding effect of the neighboring lactone oxygen, and suggested the butylidene side chain in the ligustilide moiety to have *Z*-configuration.²⁹ The linkage of the two monomers was established by the HMBC correlations (H-4' $\rightarrow$ C-3, H-8 $\rightarrow$ C-1', and H-8 $\rightarrow$ C-7'). Consequently, compound **3** was determined as a dimeric phthalide forming a cyclobutane ring at C-3 and C-8 of a butylphthalide molecule with C-3'a and C-7'a of a *Z*-ligustilide moiety. The NOESY spectrum established relative configuration of compound **3**. The correlations between H-4 and H-8, and H-4'b and H-8' excluded the *E*-configurations of two side chains. The presence of cross-peaks between H-4 and H-4'a, H-8 and H-4'a, as well as H-8 and H-7' established that these protons are in the same plane (Figure 1). Thus, **3** was determined to be a new 3-3'a, 8-7'a dimeric phthalide of *Z*-butylidenephthalide and *Z*-ligustilide, and was trivially named sinaspirolide.

The spectroscopic data (NMR, IR, and MS) of **4** were found to be similar to those of **3**. The HRESIMS spectrum of compound **4** with a protonated molecule of m/z 379.1923 (calcd for 379.1909) suggested the same molecular formula ($\text{C}_{24}\text{H}_{26}\text{O}_4$) as **3**, and the product ion spectrum of **4** also contained the same two prominent fragment ion peaks at m/z 191 and 189 found in **3**, which indicated **4** to be another dimeric phthalide. The ^1H and ^{13}C NMR data of **4** were very similar to those of **3**, and the major difference between the two was that the two vicinal olefinic protons δ 6.113 (1H, ddd, $J = 9.8, 6.4, 2.0$, H-6') and 5.994 (1H, dd, $J = 9.8, 2.8$ Hz, H-7') of **3** were not present in the ^1H NMR spectrum **4**. Instead, a doublet of an olefinic proton coupled with a methine proton [δ 3.246 (1H, dd, $J = 6.6, 1.3$ Hz, H-6')] was observed at δ 7.469. The ^{13}C spectrum of **4** showed signals for a sp^2 quaternary carbon at 133.9 and a conjugated lactone carbonyl carbon at δ 163.9, as compared to an olefinic carbon at δ 131.6 and a non-conjugated lactone carbonyl carbon at δ 173.9 observed in **3**. Comparative analysis indicated that the double bond between C-6' and C-7' in **3** was shifted to C-7' and C-7'a in **4**, which was confirmed by its HMBC correlations (H-4' $\rightarrow$ C-3; H-8 $\rightarrow$ C-5' and C-7'; H-9 $\rightarrow$ C-6'). Therefore, compound **4** was identified as a dimeric phthalide possessing a 3-3'a, 8-6' linkage, which most likely originated from the Diels-Alder Reaction with the butylidene side chain of a butylidenephthalide molecule as the dienophile. In addition, the fact that the olefinic proton of H-8' resonated at a markedly high field (δ 3.214), which is due to a shielding effect caused by its spatially neighboring aromatic ring, supported the geometry of the butylidene side chain to be *Z*-configuration. The overall relative configuration was established on the basis of the following key NOESY correlations: H-4 and H-4'a, H-8 and H-5'a, H-4'a and H-5'a, H-4'b and H-5'b, H-9a and H-6', as well as H-9b and H-6' (Figure 1). In order to indicate both the *ansa*-type and the spirocyclic partial structures of **4**, we assigned the name of ansaspirolide to this previously unreported structure.

In addition to the four new compounds described above, 17 known compounds were identified by comparison of their chemical and spectral data with literature data and/or with those of authentic samples as *p*-hydroxyphenethyl *trans*-ferulate (**5**),^{8,23,24} *Z*-ligustilide (**6**),^{21,28,30,31} *Z*-butylidenephthalide (**7**),²⁸ senkyunolide I (**8**),^{24,31} *Z*-6-hydroxy-7-methoxy-dihydroligustilide (**9**),^{11,21} imperatorin,^{32,33} ferulic acid, vanillin, *N*-butylbenzenesulphonamide (**10**),³⁴ stigmasterol,³⁵ sucrose, 11(*S*),16(*R*)-dihydroxy-octadeca-9*Z*,17-dien-12,14-diyn-1-yl acetate (**11**),³⁶ (3*R*,8*S*)-faltarindiol (**12**),³⁷ heptadeca-1-ene-9,10-epoxy-4,6-diyn-3,8-diol (**13**),³⁸ oplopandiol (**14**),³⁹ 8-hydroxy-1-methoxy-, *Z*-9-heptadecene-4,6-diyn-3-one (**15**),^{40,41} and 1,3-di-linolenin, respectively.

Imperatorin was reported from *A. archangelica*, *A. dahurica* and *A. sylvestris* previously,⁴² but not previously isolated from *A. sinensis*. *N*-butylbenzenesulphonamide (**10**) was first isolated as an antifungal antibiotic from a greenhouse soil sample,³⁴ and this is the first report of a sulfonamide from a higher plant. However, whether **10** is a natural constituent of *A. sinensis*, or an environmental contaminant sequestered during plant growth is in need of further investigation.

Compounds **11–15** are polyynes, typical constituents found in the seven dicotyledon families of the Araliaceae, Campanulaceae, Asteraceae, Pittisporaceae, Oleaceae, Santalaceae, and Apiaceae.⁴³ Of these five polyynes, 8-hydroxy-1-methoxy-, *Z*-9-heptadecene-4,6-diyn-3-one (**15**) was synthesized previously,^{40,41} but the present is the first report of this compound as a natural product. 11(*S*),16(*R*)-Dihydroxy-octadeca-9*Z*,17-dien-12,14-diyn-1-yl acetate (**11**) has been isolated from the Apiaceae and Araliaceae previously,³⁹ and displayed inhibitory activity on 5-lipoxygenase (5-LO) and cyclooxygenase (COX-1) with IC₅₀ values of 24 μ M and 73 μ M, respectively.³⁶ (3*R*,8*S*)-Falcarindiol (**12**), previously isolated from *Oplopanax horridus* and *Aegopodium podagraria*, exhibited marked antimicrobial, antibacterial, antifungal and antiproliferative activities.^{39,44,45} Heptadeca-1-ene-9,10-epoxy-4,6-diyn-3,8-diol (**13**) was originally isolated from *Panax quinquefolius*, and exhibited cytotoxic activity against L1210 leukemia cells, and the *cis* configuration of the epoxide ring in the structure of **13** was assigned by the coupling constant of *J* 4.4 Hz between H-9 and H-10.³⁸ The antibacterial and anti-TB active oplopandiol (**14**) was first obtained from *Oplopanax horridus*.³⁹ Compounds **11**, **13** and **14**, along with 1,3-di-linolenin are reported here from *A. sinensis* for the first time.

Compounds **3** and **4** are dimeric derivatives of the two monomers ligustilide and butylphthalide, formed via cycloaddition reactions as postulated in Scheme 1. Compound **3** may be regarded as a product directly formed by dimerization of two monomers via a Diels-Alder reaction, whereas compound **4** is probably generated by an alternative cycloaddition mechanism that forms the cyclobutane ring.²¹

All of the isolates were evaluated for competitive binding activity in the 5-HT₇ receptor binding assay. Compounds **5**, **11**, **12** exhibited inhibitory effects on [³H] LSD binding to the 5-HT₇ receptors with IC₅₀ values of 47.6 $\pm$ 1.2 μ M, 118.1 $\pm$ 25.7 μ M and 117.5 $\pm$ 12.0 μ M, respectively. Meanwhile, imperatorin and **15** displayed 57 $\pm$ 1 % and 69.1 $\pm$ 1 % inhibition on [³H] LSD binding to the 5-HT₇ receptors at a concentration of 100 μ M, respectively (Table 1). These compounds may at least partially contribute to the serotonergic activity of Dang Gui, and provide a rationale for its traditional use in the treatment of women's complaints, including PMS and menopausal symptoms. It remains to be clarified whether these 5-HT₇ ligands are specific binding or non-specific binding, as well agonists or antagonists to 5-HT₇ receptors.

Experimental Section

General Experimental Procedures

Optical rotation, [α]_D, values were measured on a Perkin Elmer 241 polarimeter at 20 °C. UV λ_{max} values were determined from the HPLC-PDA chromatograms. IR spectra were taken on a JASCO FT/IR-410 spectrometer. ¹H NMR and ¹³C NMR data were recorded on Bruker Avance-500, DPX-400, Avance-360, and/or DPX-300 spectrometers using CDCl₃ as a solvent and tetramethylsilane (TMS) as an internal standard. Chemical shifts (δ) were expressed in ppm with reference to TMS signals. COSY, HSQC, HMQC, NOESY and HMBC experiments were performed using standard Bruker pulse sequences. The digital resolution in 1D ¹H NMR was always better than 0.1 Hz equivalent to 0.0002 ppm (e.g., 16K real data points, 4 ppm spectral width). High-resolution mass spectra (HRMS) and tandem mass spectra (MS-MS) were obtained on a Micromass (Manchester, UK) Q-Tof-2 Quadrupole/Time of Flight mass spectrometer equipped with electrospray ion source (ESI). The spectrometer was operated in

either positive or negative ion mode. Tandem mass spectra were acquired at a collision energy of 20 eV using Ar as the collision gas at a pressure of 2.0×10^{-5} mbar. Vacuum liquid chromatography (VLC) was carried out on Merck silica gel 60 (65–400 mesh). Reverse-phase medium-pressure column chromatography (MPLC) was performed on a Merck Lobar Lichroprep RP₁₈ column, equipped with a fluid pump and an autocollector. Semi-preparative HPLC was conducted on a Waters 600 system aided by a photodiode array (PDA) detector, a Waters 717 plus autosampler, and Millennium32 Chromatography Manager (Waters Corp.) using a Watrex GROM-Sil 120 ODS-4 HE column (5 μ m, 20 $\times$ 300 mm) at a flow rate of 6 mL/min. Droplet countercurrent chromatography (DCCC) was carried out using an EYELA instrument (Model DCC-3000; Tokyo Rikakikai Co. Ltd, Japan) equipped with 300 glass columns (ID 3.4 $\times$ 400 mm), a Shimadzu LC-610 solvent pump, and an autocollector (flow rate at 0.4 mL/min, 25 min per fractions). Analytical thin-layer chromatography (TLC) was carried out on Merck TLC plates (250 μ m thickness, KGF Si gel 60 and KGF RP-18 Si gel 60) and compounds were visualized by spraying the dried plates with H₂SO₄-EtOH (1:19) or *p*-anisaldehyde-H₂SO₄-EtOH (1:1:48) followed by heating at 110 °C.

Plant Material

Dried roots of *Angelica sinensis* (Oliv.) Diels were purchased from Kiu Shun Trading Ltd., Vancouver, Canada in 2000, and identified by us by using a series of comparative macroscopic, microscopic, TLC, HPLC and PCR analysis with Dang Gui reference plant materials obtained from the National Institute for the Control of Pharmaceutical and Biological Products of China, Beijing, P.R. China (Lot # 927-200110).⁴⁶ A reference sample has been deposited at the UIC/NIH Center for Botanical Dietary Supplements Research (BC165), Chicago, IL.

Cell Culture Conditions

The human 5-HT₇-transfected Chinese hamster ovary (CHO) cell line was generously provided by David Sibley (National Institutes of Health, Bethesda, MD) and cultured with Ham's F-12 medium, containing FBS (10%), 1 mM MEM sodium pyruvate, 50 mg/mL gentamycin, and 50 units/mL each of penicillin and streptomycin.

Membrane Preparation

Cells (human 5-HT₇ CHO) were plated into dishes (150 mm $\times$ 10 mm) and cultured to confluence in order to collect membranes as previously described.⁴⁷ A hypotonic buffer (15 mM Tris, 1.25 mM MgCl₂, and 1 mM EDTA, pH 7.4) was added to the dishes and incubated at 4 °C for 15 min, the cells were scraped from the dishes, and the lysate was centrifuged. The hypotonic buffer was removed and the membrane pellet resuspended in TEM buffer (75 mM Tris, 1 mM EDTA, 12.5 mM MgCl₂, pH 7.4). The cell membranes were homogenized and centrifuged twice at 12000g for 20min. The pellets were dissolved in TEM buffer and were stored at –80 °C. Protein concentrations were determined according to the Lowry method using bovine serum albumin as the standard.

Serotonin Receptor Binding Assays

Initial radioligand binding studies were performed by Panlabs (Bothell, WA) as previously described for serotonin receptor subtypes 1A, 1B, 1D, 2A, 2B, 2C, 3, 5A, 6, and 7.^{48–54} Assays were performed in-house with minor modifications using human recombinant CHO cell membrane and [³H] LSD (5 nM) in an incubation buffer (75 mM Tris-HCl, 1.25 mM MgCl₂, 1 mM EDTA, pH 7.4).⁵⁴ After a 1-h incubation at 37 °C, the mixture for receptor was filtered over 934-AH Whatman filters that had been presoaked in 0.5% polyethylenimine (PEI) and washed twice in ice-cold 50 mM Tris buffer (pH 7.4) using a 96-well Tomtec-Harmester (Orange, CT). Each filter was dried, suspended in Wallac microbeta plate scintillation fluid (PerkinElmer life Sciences, Boston, MA), and counted with a Wallac 1450 Microbeta liquid

scintillation counter (PerkinElmer Life Sciences, Boston, MA). 5-hydroxytryptamine (serotonin, 5-HT) (250 nM) was used to define nonspecific binding, which accounted for <10% of the total binding. The percent inhibition of [³H] ligand bound to each 5-HT receptor was determined as $[1 - (\text{dpm}_{\text{sample}} - \text{dpm}_{\text{blank}}) / (\text{dpm}_{\text{DMSO}} - \text{dpm}_{\text{blank}})] \times 100$, and the extracts and fractions displaying inhibition percentage over 50% were regarded as active, and subjected to further fractionation in our experiment. The IC₅₀ values were determined for the isolates with percent inhibition greater than 50%. The data represent the average $\pm$ SD of at least triplicate determinations.

Extraction and Isolation

The milled roots (8.0 kg) of Dang Gui were macerated in 20 L of MeOH for 24 hours, and then percolated exhaustively with the same solvent (total 40 L). The MeOH percolate was evaporated to a volume of *ca.* 2700 mL (E₀). After 200 mL of the MeOH percolate was evaporated to dryness for use in bioassay evaluation, to the remaining 2500 mL was added 500 mL of water and then partitioned against petroleum ether (PE, 2000 mL $\times$ 3). The PE extract (E₁, 268 g; 5-HT₇ 69.0 $\pm$ 3.0 % inhib. at 100 μ g/mL) was obtained *in vacuo* by rotary evaporation. The aqueous-methanol mother liquid was evaporated *in vacuo* to remove MeOH, and the resulting aqueous extract was successively partitioned with CHCl₃ (2000 mL $\times$ 3) and *n*-BuOH (2000 mL $\times$ 3). The CHCl₃ (E₂, 57 g; 5-HT₇ 51.0 $\pm$ 3.0 % inhib. at 100 μ g/mL) and *n*-BuOH extracts (E₃, 39 g; 5-HT₇ 27.0 $\pm$ 1.0 % inhib. at 100 μ g/mL) were acquired after being dried *in vacuo*, respectively. The aqueous mother liquid was lyophilized to afford an aqueous extract (E₄, 158 g; 5-HT₇ 28.0 $\pm$ 9.0 % inhib. at 100 μ g/mL). The MeOH extract (E₀; 5-HT₇ 59.0 $\pm$ 4.0 % inhib. at 100 μ g/mL) and its partitions (E₁–E₄) were evaluated for their serotonergic activities in the 5-HT₇ receptor binding assay.

Bioassay results showed that partitions E₁ and E₂ exhibited serotonergic activities with 69.0 $\pm$ 0 % and 51.0 $\pm$ 3.0 % inhibitory effects on [³H] LSD binding to the 5-HT₇ receptors at a concentration of 100 μ g/mL, respectively. Therefore, both the PE (E₁) and the CHCl₃ partitions (E₂) were selected for bioassay-guided fractionation. The pooled E₁ and E₂ were subjected to flash column chromatography eluting with a stepwise gradient solvent system of PE-EtOAc (10:0 $\rightarrow$ 0:10) and EtOAc-MeOH (10:0 $\rightarrow$ 0:10) to afford thirteen primary pooled fractions (F1–F13).

Primary fraction F5 (7.0 g) was chromatographed over silica gel (600 g, 60–200 mesh, 9 $\times$ 30 cm column) using the vacuum liquid chromatography (VLC) technique eluting with gradients of PE-EtOAc-MeOH (100:0:0 $\rightarrow$ 0:0:100) to give fourteen secondary fractions (F5-1 to F5-14). Stigmasterol (20 mg) was precipitated from secondary fraction F5-4 at room temperature. The secondary fraction F5-5 (4.5 g) was further separated on a VLC column packed with silica gel (70 g, 230–400 mesh, 1.5 $\times$ 10 cm) and eluting with a PE-EtOAc stepwise gradient (100:0 $\rightarrow$ 0:100) to afford seven tertiary fractions F5-5-1 to F5-5-7. Further purification of F5-5-2 (500 mg) by reverse-phase preparative HPLC (75% aqueous MeOH $\rightarrow$ 99% MeOH, 6 mL/min) resulted in the isolation of **2** (3.0 mg, *t_R* = 33 min), **3** (2.2 mg, *t_R* = 55 min), **10** (1.9 mg, *t_R* = 18.5 min), **12** (90.0 mg, *t_R* = 73 min), **13** (1.4 mg, *t_R* = 46 min), **14** (1.6 mg, *t_R* = 91 min) and **15** (0.7 mg, *t_R* = 94 min). Fraction F5-5-3 was also subjected to reverse-phase preparative HPLC (6 mL/min) using an isocratic condition (MeOH-H₂O, 78:22) to afford imperatorin (2.0 mg, *t_R* = 31 min), ferulic acid (1.3 mg, *t_R* = 14 min) and vanillin (2.0 mg, *t_R* = 13 min).

Primary fraction F3 (43.2 g) was initially fractionated by VLC (6 $\times$ 30 cm) on silica gel (220–400 μ m, 500 g), eluting with a gradient of PE-EtOAc starting from 100% PE to 50% PE in EtOAc to afford thirteen secondary fractions (F3-1 to F3-13). Secondary fractions F3-7 (3.6 g) and F3-8 (6.3 g) were combined together based on their TLC profiles and subjected to preparative RP-18 MPLC (3 $\times$ 25 cm, 80 g) eluted with a MeOH-H₂O (70% MeOH $\rightarrow$ 98% MeOH) gradient to afford 1,3-di-linolenin (2.3 mg). The tertiary fraction F3-7-10 was further

purified by preparative HPLC eluted with isocratic 70% aqueous MeOH to afford compounds **6** (50.0 mg, t_R = 44 min), **7** (30.0 mg, t_R = 48 min), and **8** (3.8 mg; t_R = 14 min).

The primary fraction F7 (4.0 g) was chromatographed by VLC over a silica gel column (500 g, 100–230 mesh) with a stepwise gradient of hexane-CHCl₃-EtOAc-MeOH (20:80:0:0 → 0:0:0:100) to give nine pooled secondary fractions (F7-1 to F7-9). Fraction F7-5 (1.6 g) was subjected to an ascending mode of DCCC with flow rate at 0.4 mL/min, using two-phase solvent system of PE-EtOAc-MeOH-H₂O (6:4:6:4). The pooled tertiary fraction F7-5-8 (150 mg) was further purified by RP-C18 HPLC using a gradient of MeCN-H₂O (60% MeCN → 98% MeCN in H₂O) to afford compound **4** (1.0 mg; t_R = 48 min). Fractions F7-7 (400 mg) and F7-8 (400 mg) were re-chromatographed over a RP-C18 Lobar® column (40–63 μm) and eluted with a gradient of MeOH-H₂O (50% → 100% MeOH), and led to the tertiary fractions F7-7-5 (39.0 mg) and F7-8-5 (60.0 mg), respectively. F7-7-5 was further purified by RP-C18 HPLC eluting with isocratic MeCN-H₂O (70:30) to give compound **5** (11.7 mg; t_R = 42 min). F7-8-5 was purified by RP-C18 HPLC with a MeCN-H₂O gradient (50% MeCN → 95% MeCN in H₂O) to afford compound **9** (2.0 mg; t_R = 44 min). F7-8-8 (37.9 mg) was purified by preparative TLC (1 mm, 20 cm × 20 cm) developed with CH₂Cl₂-EtOAc (7:3) and monitored under UV₂₅₄ nm to yield compound **11** (8.7 mg, R_f = 0.6).

Primary fraction F10 (5.6g) was chromatographed over silica gel (500 g, 220–400 mesh, 7 × 31 cm) using the VLC technique eluting with a gradient of CH₂Cl₂-EtOAc-MeOH (100:0:0 → 0:0:100) to afford secondary fraction F10-10 (120 mg), which was subjected to reverse-phase preparative HPLC (55% MeOH in H₂O, 6 mL/min) to yield compound **1** (10.0 mg, t_R = 32 min).

Sucrose was crystallized directly from the MeOH crude extract (E₀) at room temperature.

Angeliferulate (1): pale yellow oil; $[\alpha]_D^{20} +2^\circ$ (c 0.2, CH₂Cl₂); UV (LC-PDA) λ_{max} 326 nm; IR λ_{max} (CH₂Cl₂) 3385 (broad) (OH), 2920, 1701 (CO₂R), 1600, 1515 (Ph), 1430, 1267, 1159, 1034 cm⁻¹; ¹H NMR (CDCl₃, 360 MHz) δ 7.588 (1H, d, J = 16.0 Hz, H-7), 7.061 (1H, dd, J = 8.2, 2.0 Hz, H-6), 7.030 (1H, d, J = 2.0 Hz, H-2), 6.915 (1H, d, J = 8.2 Hz, H-5), 6.905 (1H, d, J = 8.6 Hz, H-5'), 6.810 (1H, d, J = 2.0 Hz, H-2'), 6.806 (1H, dd, J = 8.6, 2.0 Hz, H-6'), 6.322 (1H, d, J = 16.0 Hz, H-8), 4.148 (1H, dd, J = 13.0, 3.1 Hz, H-9'a), 4.116 (1H, d, J = 11.8 Hz, H-7'), 3.983 (1H, m, H-8'), 3.981 (1H, m, H-9'b), 3.929 (3H, s, OCH₃-3), 3.889 (3H, s, OCH₃-3'), 3.278 (3H, s, OCH₃-7'); ¹³C NMR (CDCl₃, 90 MHz) δ 167.4 (C-9), 148.4 (C-4), 147.2 (C-3'), 147.1 (C-3), 146.3, (C-4'), 145.7 (C-7), 129.6 (C-1'), 127.2 (C-1), 123.6 (C-6), 121.1 (C-6'), 115.3 (C-8), 115.1 (C-5'), 114.8 (C-5), 109.6 (C-2), 109.5 (C-2'), 84.7 (C-7'), 74.1 (C-8'), 65.0 (C-9'), 57.0 (OCH₃-7'), 56.3 (OCH₃-3'), 56.0 (OCH₃-3); HRESIMS [M - H] - 403.1380 m/z calcd for C₂₁H₂₄O₈ (-3.3 ppm) ESIMSMS product ions m/z (% base peak) 371 (100), 193 (83), 341 (37), 175 (19), 403 (18), 327 (17).

10-Angeloylbutylphthalide (2): pale yellow oil; $[\alpha]_D^{20} -16^\circ$ (c 0.1, CH₂Cl₂); UV (LC-PDA) λ_{max} 226, 274 nm; IR λ_{max} (CH₂Cl₂) 2918, 1765, 1699, 1235, 1162, 1061 cm⁻¹; ¹H NMR (CDCl₃, 360 MHz) δ 7.912 (1H, dd, J = 7.6, 1.2 Hz, H-7), 7.685 (1H, ddd, J = 7.7, 7.6, 1.2 Hz, H-5), 7.542 (1H, ddd, J = 7.7, 7.6, 0.8 Hz, H-6), 7.427 (1H, dd, J = 7.6, 0.8 Hz, H-4), 6.055 (1H, qq, J = 7.3, 1.5, H-3'), 5.490 (1H, dd, J = 7.2, 3.9 Hz, H-3), 5.000 (1H, m, H-10), 2.205 (1H, m, H-8b), 1.975 (3H, dq, J = 7.3, 1.5, H-4'), 1.885 (3H, dq, J = 1.5, 1.5, H-5'), 1.823 (1H, m, H-9b), 1.776 (1H, m, H-8a), 1.721 (1H, m, H-9a), 1.265 (2H, d, J = 6.4 Hz, H-11); ¹³C NMR (CDCl₃, 90 MHz) δ 170.9 (C-1), 168.0 (C-1'), 149.9 (C-3a), 137.9 (C-3'), 134.5 (C-5), 129.6 (C-6), 128.4 (C-2'), 126.5 (C-7a), 126.2 (C-7), 122.0 (C-4), 81.3 (C-3), 70.4 (C-10), 31.5 (C-9), 31.3 (C-8), 21.0 (C-5'), 20.4 (C-11), 16.1 (C-4'); HRESIMS [M + Na]⁺ 311.1297 m/z

calcd for $C_{17}H_{20}O_4$ (4.4 ppm); ESIMSMS product ions m/z (% base peak) 189 (100) 171 (83) other product ions 153 (8), 145 (16), 133 (10), 83 (6).

Sinaspirolide (3): pale yellow oil; $[\alpha]_D^{20} +24^\circ$ (c 0.1, CH_2Cl_2); UV (LC-PDA) λ_{max} 280 nm; IR λ_{max} (CH_2Cl_2) 2929, 1776, 1700, 1080, 1035 cm^{-1} ; 1H NMR ($CDCl_3$, 400 MHz) δ 7.901 (1H, dd, $J = 7.4, 1.2$ Hz, H-7), 7.710 (1H, td, $J = 7.6, 1.2$ Hz, H-5), 7.586 (1H, dd, $J = 7.6, 7.4$ Hz, H-6), 7.577 (1H, brd, $J = 7.6$ Hz, H-4), 6.113 (1H, ddd, $J = 9.8, 6.4, 2.0$, H-6'), 5.994 (1H, dd, $J = 9.8, 2.8$ Hz, H-7'), 4.406 (1H, t, H-8'), 3.016 (1H, dd, $J = 7.8, 7.8$ Hz, H-8), 2.246 (1H, m, H-9'a), 2.151 (1H, m, H-5'a), 2.147 (1H, m, H-9'b), 2.091 (1H, m, H-4'a), 1.990 (1H, m, H-5'b), 1.790 (1H, dddd, $J = 14.1, 10.2, 7.8, 5.4$, H-9a), 1.634 (1H, ddd, $J = 12.4, 3.7, 2.0$, H-4' b), 1.510 (1H, dddd, $J = 18.0, 10.2, 7.8, 5.4$, H-9b), 1.399 (1H, m, H-10'a), 1.256 (1H, m, H-10' b), 1.220 (1H, m, H-10a), 1.010 (1H, m, H-10b), 0.885 (3H, t, $J = 7.4$, H-11'), 0.776 (3H, t, $J = 7.4$, H-11); ^{13}C NMR ($CDCl_3$, 100 MHz) δ 173.9 (C-1'), 168.5 (C-1), 148.2 (C-3'), 146.8 (C-3a), 134.0 (C-5), 131.6 (C-6'), 130.2 (C-6), 126.8 (C-7a), 126.4 (C-7), 124.8 (C-7'), 123.3 (C-4), 106.5 (C-8'), 88.5 (C-3), 54.2 (C-3'a), 53.0 (C-8), 48.6 (C-7'a), 27.7 (C-9), 27.4 (C-9'), 23.3 (C-4'), 22.8 (C-10'), 21.2 (C-5'), 20.6 (C-10), 14.1 (C-11), 13.8 (C-11'); HRESIMS $[M + H]^+$ 379.1909 m/z calcd for $C_{24}H_{27}O_4$ (3.3 ppm); ESIMSMS product ions m/z (% base peak) 191 (100) 189 (16).

Ansaspirolide (4): colorless oil; $[\alpha]_D^{20} +3^\circ$ (c 0.1, CH_2Cl_2); UV (LC-PDA) λ_{max} 277 nm; IR λ_{max} (CH_2Cl_2) 2922, 1772, 1700, 1466, 1270, 1079, 1021 cm^{-1} ; 1H NMR ($CDCl_3$, 500 MHz) δ 7.886 (1H, d, $J = 7.5$ Hz, H-7), 7.760 (1H, t, $J = 7.5$ Hz, H-5), 7.608 (1H, t, $J = 7.5$ Hz, H-6), 7.535 (1H, d, $J = 7.5$ Hz, H-4), 7.469 (1H, d, $J = 6.6$, H-7'), 3.246 (1H, dd, $J = 6.6, 1.3$ Hz, H-6'), 3.214 (1H, $J = 8.6, 6.8$ Hz, H-8'), 2.261 (1H, dt, $J = 6.9, 1.3$ Hz, H-8), 2.218 (1H, m, H-4'a), 2.045 (1H, m, H-9'a), 1.904 (1H, m, H-5'a), 1.739 (1H, m, H-9'b), 1.560 (1H, m, H-5' b), 1.503 (1H, m, H-4'b), 1.206 (1H, m, H-10b), 1.176 (2H, m, H-9), 1.015 (1H, m, H-10'a), 1.085 (1H, m, H-10'b), 1.002 (1H, m, H-10a), 0.736 (3H, t, $J = 7.0$, H-11), 0.679 (3H, t, $J = 7.3$, H-11'); ^{13}C NMR ($CDCl_3$, 125 MHz) δ 168.9 (C-1), 163.9 (C-1'), 149.4 (C-3a), 147.8 (C-3'), 140.7 (C-7'), 133.9 (C-7'a), 133.9 (C-5), 129.8 (C-7a), 129.8 (C-6), 125.7 (C-7), 122.1 (C-4), 107.4 (C-8'), 90.7 (C-3), 52.0 (C-3'a), 52.0 (C-8), 38.3 (C-6'), 32.6 (C-9), 26.9 (C-9'), 25.4 (C-4'), 25.1 (C-5'), 22.3 (C-10'), 21.4 (C-10), 14.0 (C-11), 13.5 (C-11'); HRESIMS $[M + H]^+$ 379.1923 m/z calcd for $C_{24}H_{26}O_4$ (3.6 ppm); ESIMSMS product ions m/z (% base peak) 189 (100) 191 (83).

Acknowledgements

This research was jointly funded by grant P50 AT00155 through the National Center for Complementary and Alternative Medicine (NCCAM), the Office of Dietary Supplements (ODS), the National Institute of General Medical Sciences (NIGMS), and the Office for Research on Women's Health (ORWH). We are grateful to Dr. David Lankin, Department of Medicinal Chemistry and Pharmacognosy of the College of Pharmacy, for his expertise NMR support and discussion, and to Dr. Robert Kleps of the UIC Research Resources Center University of Illinois at Chicago, for providing excellent NMR facilities.

References and Notes

1. Pharmacopoeia of the People's Republic of China-Radix Angelica sinensis. 1. Chemical Industry; Beijing, P.R. China: 2000.
2. Upton, R. American Herbal Pharmacopoeia and Therapeutic Compendium-Dang Gui Root Scotts Valley. CA, USA: 2003.
3. WHO monographs on selected medicinal plants. Radix Angelicae sinensis. 2. 2002.
4. Read BE. J Obstet Gynaecol 1927;34:498–508.
5. Liu J, Burdette JE, Xu H, Gu C, van Breemen RB, Bhat KP, Booth N, Constantinou AI, Pezzuto JM, Fong HH, Farnsworth NR, Bolton JL. J Agr Food Chem 2001;49:2472–2479. [PubMed: 11368622]
6. Hirata JD, Swiersz LM, Zell B, Small R, Ettinger B. Fertil Steril 1997;68:981–986. [PubMed: 9418683]

7. Huang W, Song C. *Zhongguo Zhongyao Zazhi* 2001;26:147–151. 155. [PubMed: 12525030]
8. Zschocke S, Liu J, Stuppner H, Bauer R. *Phytochem Anal* 1998;9:283–290.
9. Chen Y. *Gansu Yaoxue* 1984;1:4–8.
10. Zhang H, Li Z, Chen Y. *Lanzhou Daxue Xuebao, Ziran Kexueban* 1989;25:78–81.
11. Lin L, He X, Lian L, King W, Elliott J. *J Chromatogr A* 1998;810:71–79.
12. Xiao L. *Zhong Cheng Yao* 1989;11:35–36.
13. Mei QB, Tao JY, Cui B. *Chinese Med J* 1991;104:776–781.
14. Lin M, Zhu C, Sun Q, Fang Q. *Yaoyue Xuebao* 1979;14:529–534.
15. Wang H, Chen R, Xu H. *Zhongguo Zhongyao Zazhi* 1998;23:167–168. [PubMed: 11596237]
16. Sheu SJ, Ho YS, Chen YP, Hsu HY. *Planta Med* 1987;53:377–378. [PubMed: 3671555]
17. Zschocke S, Klaiber I, Bauer R, Vogler B. *Mol Divers* 2005;9:33–39. [PubMed: 15789549]
18. Lu X, Liang H, Zhao Y. *Zhongguo Zhongyao Zazhi* 2003;28:423–425. [PubMed: 15139126]
19. Hon P, Lee C, Choang TF, Chui K, Wong HNC. *Phytochemistry* 1990;29:1189–1191.
20. Su D, Yu S, Qin H. *Acta Pharmaceut Sinica* 2005;40:141–144.
21. Kaouadji M, De Pachtere F, Pouget C, Chulia AJ, Lavaitte S. *J Nat Prod* 1986;49:872–877.
22. Quiroz-Garcia B, Figueroa R, Cogordan JA, Delgado G. *Tetrahedron Lett* 2005;46:3003–3006.
23. Darwish FMM, Reinecke MG. *Phytochemistry* 2003;62:1179–1184. [PubMed: 12648532]
24. Kobayashi M, Fujita M, Mitsunashi H. *Chem Pharm Bull* 1987;35:1427–1433.
25. El-Gamal AA, Takeya K, Itokawa H, Halim AF, Amer MM, Saad HA, Awad SA. *Natural Medicines* 1994;48:304–6.
26. Nakatani N, Inatani R, Fuwa H. *Agr Biol Chem* 1980;44:2831–2836.
27. Banerjee SK, Gupta BD, Sheldrick WS, Hoefle G. *Liebigs Ann* 1984:888–893.
28. Gijbels MJM, Scheffer JJC, Baerheim Svendsen A. *Planta Med* 1982;44:207–211. [PubMed: 17402120]
29. Tsuchida T, Kobayashi M, Kaneko K, Mitsunashi H. *Chem Pharm Bull* 1987;35:4460–4464.
30. Wang P, Gao X, Wang Y, Fukuyama Y, Miura I, Sugawara M. *Phytochemistry* 1984;23:2033–2038.
31. Fischer FC, Gijbels MJM. *Planta Med* 1987;53:77–80. [PubMed: 17268969]
32. Masuda T, Takasugi M, Anetai M. *Phytochemistry* 1998;47:13–16.
33. Liu R, Li A, Sun A, Kong L. *J Chromatogr A* 2004;1057:225–228. [PubMed: 15584243]
34. Kim KK, Kang JG, Moon SS, Kang KY. *J Antibiot* 2000;53:131–136. [PubMed: 10805572]
35. Xie D, Wang L, Ye H, Li G. *Plant Cell Tiss Org* 2001;63:161–166.
36. Liu JH, Zschocke S, Bauer R. *Phytochemistry* 1998;49:211–213.
37. Zheng G, Lu W, Cai J. *J Nat Prod* 1999;62:626–628. [PubMed: 10217726]
38. Fujimoto Y, Satoh M, Takeuchi N, Kirisawa M. *Chem Pharm Bull* 1991;39:521–523. [PubMed: 2054881]
39. Kobaisy M, Abramowski Z, Lermer L, Saxena G, Hancock REW, Towers GHN, Dohsee D, Stokes RW. *J Nat Prod* 1997;60:1210–1213. [PubMed: 9392889]
40. Bohlmann F, Arndt C, Bornowski H, Kleine K. *Chem Ber* 1961;94:958–967.
41. Schulte KE, Potter B. *Arch Pharm* 1977;310:945–963.
42. Murphy EM, Nahar L, Byres M, Shueb M, Siakalima M, Rahman MM, Gray AI, Sarker SD. *Biochem Syst Ecol* 2004;32:203–207.
43. Hansen L, Boll PM. *Phytochemistry* 1986;25:285–293.
44. Furumi K, Fujioka T, Fujii H, Okabe H, Nakano Y, Matsunaga H, Katano M, Mori M, Mihashi K. *Bioorg Med Chem Lett* 1998;8:93–96. [PubMed: 9871635]
45. Kemp MS. *Phytochemistry* 1978;17:1002.
46. Deng, S.; Fabricant, DS.; Pauli, GF.; Fong, HHS.; Farnsworth, NR. Identification of *Angelica sinensis* by a series of analytical techniques. 44th Annual Meeting of American Society of Pharmacognosy; Chapel Hill, North Carolina. 2003.
47. Albert PR, Zhou QY, Van Tol HHM, Bunzow JR, Civelli O. *J Biol Chem* 1990;265:5825–5832. [PubMed: 2156831]

48. Domenech T, Beleta J, Palacios JM. *N-S Arch Pharmacol* 1997;356:328–334.
49. Miller K, Weisberg E, Fletcher PW, Teitler M. *Synapse* 1992;11:58–66. [PubMed: 1318585]
50. Rees S, den Daas I, Foord S, Goodson S, Bull D, Kilpatrick G, Lee M. *FEBS Lett* 1994;355:242–6. [PubMed: 7988681]
51. Wolf WA, Schutz LJ. *J Neurochem* 1997;69:1449–1458. [PubMed: 9326273]
52. Bonhaus DW, Bach C, DeSouza A, Salazar RHR, Matsuoka BD, Zuppan P, Chan HW, Eglen RM. *Brit J Pharmacol* 1995;115:622–628. [PubMed: 7582481]
53. Martin GR, Humphrey PP. *Neuropharmacology* 1994;33:261–273. [PubMed: 7984266]
54. Roth BL, Craig SC, Choudhary MS, Uluer A, Monsma FJ, Shen Y, Meltzer HY, Sibley DR. *J Pharmacol Exp Ther* 1994;268:1403–1410. [PubMed: 7908055]

Figure 1. Key NOESY correlations for compound 3 and 4

The NOESY spectrum established relative configuration of compound **3**. The Z-configurations of butyl and butylidene side chains were indicated by correlations between H-4 and H-8, as well as H-4'b and H-8', respectively. In addition, the correlations between H-4 and H-4'a, H-8 and H-4'a, along with H-8 and H-7' suggested that these protons are on the same face of molecule. Key NOESY correlations of **4** were between H-4 and H-4'a, as well as H-8 and H-5' a. This not only suggested that butyl side chain possesses Z-configuration, but also defined the relative spatial positions of two six-membered rings as shown in this model.

Scheme 1.
Postulated biosynthetic pathways of dimers **3** and **4**.

Structures.

Table 1Competitive binding activities to 5-HT₇ receptors of the isolates from *Angelica sinensis*.

Isolates	Inhibition % (100 μ M) ^a	IC ₅₀ ^a (μ M)	Isolates	Inhibition % (100 μ M) ^a	IC ₅₀ ^a (μ M)
1	31 ± 6		11	49 ± 4	118.1 ± 25.7
2	21 ± 6		12	61 ± 8	117.5 ± 12.0
3	24 ± 6		13	5 ± 4	
4	19 ± 0		14	36 ± 16	
5	71 ± 7	47.6 ± 1.2	15	69 ± 1	>150
6	33 ± 8		imperatorin	57 ± 2	
7	46 ± 10	126.6 ± 20.8	stigmasterol	0 ± 3	
8	0 ± 1		ferulic acid	41 ± 4	
9	36 ± 13		vanillin	0 ± 11	
10	0 ± 4		1,3-di-linolenin	0 ± 13	

^aIC₅₀ values represent the concentration (μ M) that shows 50 % inhibition of binding activities. All data represent average ± SD of triplicate determinations.Positive control: Serotonin (IC₅₀ = 2.5 ± 0.7 nM)